Tesofensine vs Amycretin

Tesofensine and Amycretin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

Tesofensine functions as a triple monoamine reuptake inhibitor, specifically targeting serotonin, norepinephrine, and dopamine pathways. Originally developed for neurodegenerative diseases such as Alzheimer's and Parkinson's, it has been repurposed for obesity treatment due to its appetite-suppressing properties. Research indicates that Tesofensine can lead to an approximate 10% reduction in body weight, attributed to its ability to decrease caloric intake and enhance resting metabolic rate. In clinical trials, particularly those conducted by NeuroSearch A/S and later Saniona, the compound demonstrated significant weight loss outcomes, although the evidence is primarily derived from Phase 2 studies, with ongoing Phase 3 trials expected to provide further validation. Limitations of the current evidence include the relatively small sample sizes and the need for long-term data on safety and efficacy.

Amycretin represents a novel approach to obesity treatment as a unimolecular peptide co-agonist, activating both GLP-1 and amylin receptors from a single molecule. Developed by Novo Nordisk, its unique dual-action mechanism is designed to enhance weight loss through synergistic effects on appetite regulation and glucose metabolism. Studies indicate that Amycretin can facilitate significant weight loss via an oral tablet formulation, with ongoing Phase 3 trials anticipated to commence in 2026. Notably, its dual receptor engagement sets it apart from traditional GLP-1 agonists, such as orforglipron, which do not possess the same level of receptor interaction. The current body of evidence is still emerging, and while preliminary data suggest promising outcomes, further research is necessary to establish comprehensive efficacy and safety profiles.

Both Tesofensine and Amycretin are under investigation primarily for their roles in weight loss, highlighting their potential in addressing obesity. Tesofensine has been specifically studied for its appetite suppression capabilities, which contribute to its weight loss effects. Conversely, Amycretin is being explored not only for weight loss but also for broader applications in obesity treatment and metabolic health, leveraging its dual receptor activity. This divergence in research focus illustrates the distinct mechanisms and potential therapeutic benefits offered by each peptide, guiding researchers in selecting the appropriate compound for their specific study objectives.

Safety profiles for Tesofensine and Amycretin reveal important considerations for their use in research. For Tesofensine, Phase 2 trials indicated an increase in heart rate (5-8 bpm) and elevated blood pressure at higher doses. Common adverse effects reported include dry mouth, insomnia, constipation, nausea, and diarrhea, alongside psychiatric effects such as anxiety and mood changes, which are consistent with the pharmacological action of monoamine reuptake inhibitors. In contrast, Amycretin's adverse events are primarily gastrointestinal, encompassing nausea, vomiting, and diarrhea, typical of the GLP-1 agonist class. These gastrointestinal effects are generally mild to moderate and tend to diminish with continued treatment. A Phase 1 trial (Gasiorek et al., Lancet 2025) noted that Amycretin was well-tolerated across various dose ranges, although comprehensive safety data will be essential as research progresses.